Albert Grinshpun: Combining chemo with SERD in TP53wt ESR1mut breast cancers

Albert Grinshpun,  Goldfarb Advanced Breast Cancer Fellow at the Breast Oncology Center of Dana-Farber Cancer Institute, shared a post on X:

“Finally out! We show that combining chemo with SERD is additive, especially in TP53wt ESR1mut breast cancers. The tx paradigm of ER+ MBC should be reconsidered; perhaps we should keep the anti-ER along the way similar to anti-HER2 tx in HER2+ MBC.”

Read further.
Source: Albert Grinshpun/X